February 2026 UPMC for You and UPMC Community HealthChoices formulary update
Feb. 2026Pharmacy Updates
Pulmicort Flexhaler has a new distributor, Rubicon Holding. National Drug Codes (NDCs) for Pulmicort Flexhaler from Rubicon Holding are not included in the Medicaid Drug Rebate program and are not covered under the Medicaid Prescription Drug Program. Pulmicort Flexhaler NDCs from the previous manufacturer, H2 Pharma, have been discontinued but may be billed/dispensed until supplies are exhausted.
To avoid denials at the pharmacy, prescribers are encouraged to begin transitioning current Pulmicort Flexhaler patients to covered alternatives as soon as possible.
Preferred/Covered PDL alternatives for Pulmicort Flexhaler include the following*:
- Arnuity Ellipta
- Asmanex HFA
- Asmanex Twisthaler
- Budesonide 0.25 mg/2 mL and 0.5 mg/2 mL Respules
- Qvar Redihaler
- Fluticasone Propionate HFA for patients < 19 years old
*The DHS PDL is subject to review and may be revised periodically.
Recent Announcements
Asymptomatic Severe Coronary Disease: Detection to Decisions. Do We Know The Proper Management?
In this new CME course, Krishna V. Tummalapalli, MD, interventional cardiologist, UPMC Heart and Vascular Institute, discusses how to explain the importance of early detection of coronary artery disease, as well as how to describe how early identification can reduce future cardiovascular events and identify appropriate first line medical therapy strategies for patients with asymptomatic stable ischemic heart disease.Mar. 2026Education/Webinars
CME Webinar Series: Introducing Physicians and their teams to Value-Based Health Care
Please join us for a new CME-accredited webinar series on value-based care. This series is designed to introduce practicing physicians and their teams to value-based health care. Over the course of six sessions, we will define the components of value and identify the tools necessary to deliver high-value care for a population.Feb. 2026Education/Webinars